An interventional study of flaxseed oil and pomegranate dry extract and sunflower oil and microcrystalline cellulose in Chronic Kidney Diseases, Dialysis; Complications and Inflammation, sponsored by Santa Catarina Federal University. Completed at 1 site in Brazil. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2022-10-04.
Sponsored by Santa Catarina Federal University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 134 studies in Renal Insufficiency, Chronic with a site in Brazil — 23 open to participants now, 39 under way, 15 of them phase 3. Renal Insufficiency, Chronic · Brazil.
Among the 134 studies in Renal Insufficiency, Chronic with a site in Brazil, this one is the 81st largest by enrollment of the 123 interventional ones that give a count, is one of 11 that started in 2021, is one of 52 with no phase, and was the 95th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →23 of the 134 studies in Renal Insufficiency, Chronic with a site in Brazil are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Brazil, United States, Argentina and 24 more countries
Ages 18–99
AstraZeneca · Sites in Brazil, United States, Argentina and 34 more countries
Ages 18+
Eli Lilly and Company · Sites in Brazil, Argentina, Australia and 35 more countries
Ages 50+
Universidade Federal Fluminense · Sites in Brazil
Ages 18–65
Hospital Alemão Oswaldo Cruz · Sites in Brazil
Ages 18+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
134 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 45 · Phase 4 9
First in 2002; this study’s year is marked. 11 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 100 across the 123 interventional studies, 4,613 across the 11 observational. Of the 78 that completed or were terminated, 32 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 134 have an industry lead sponsor. The 10 most frequent:
Santa Catarina Federal University is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Santa Catarina Federal University has 1 study filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
12 of the studies in Renal Insufficiency, Chronic with a site in Brazil that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT07118683Hospital Alemão Oswaldo CruzBRAZILIAN REGISTRY OF CHRONIC NON-COMMUNICABLE DISEASES IN PEOPLE LIVING WITH HIV/AIDS | 2026-11 |
| NCT06402851Hospital Sirio-LibanesVitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE) | 2026-12 |
Add all 12 to your calendar (.ics) → With an account.
Among the 134 studies in Renal Insufficiency, Chronic with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Nutritional and metabolic alterations in patients with chronic kidney disease (CKD) such as inflammation, oxidative stress, dyslipidemia, and poor nutritional status which associate with poor clinical outcome can potentially be targeted and ameliorated by interventions using nutritional supplements. The investigators evaluated the effects of 8 weeks of oral supplementation with flaxseed oil and pomegranate dry extract on markers of inflammation, lipid profile and nutritional status of individuals undergoing hemodialysis (HD).
The goal of this randomized, placebo-controlled, double-blind clinical trial is to evaluate the effects of 8 weeks of oral supplementation with flaxseed oil and pomegranate dry extract on markers of inflammation, lipid profile and nutritional status of individuals undergoing hemodialysis (HD).
Participants will be randomly assigned, in a 1:1 ratio, to supplementation group to receive twice a day 1 capsule of 1.000 mg of flaxseed oil plus 1 capsule of 600mg of pomegranate dry extract; or to placebo group, to receive twice a day 1 capsule of 1.000 mg of sunflower oil plus 1 capsule of 600mg of microcrystalline celulose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2g daily of flaxseed oil plus 1.2g daily pomegranate dry extract
Dietary Supplement: flaxseed oil and pomegranate dry extract
2g daily of sunflower oil plus 1.2g daily microcrystalline cellulose
Dietary Supplement: sunflower oil and microcrystalline cellulose
The flaxseed oil were yellow capsules with 1.0 g each and the pomegranate dry extract capsules were green with 0.6 g each.
The sunflower oil were yellow capsules with 1.0 g each and the microcrystalline cellulose capsules were green with 0.6 g each.
interleukin 2
Time frame: Change from Baseline and at 8 weeks (end of study)
interleukin 4
Time frame: Change from Baseline and at 8 weeks (end of study)
interleukin 6
Time frame: Change from Baseline and at 8 weeks (end of study)
interleukin 10
Time frame: Change from Baseline and at 8 weeks (end of study)
tumor necrosis factor alpha
Time frame: Change from Baseline and at 8 weeks (end of study)
interferon-gamma
Time frame: Change from Baseline and at 8 weeks (end of study)
C-reactive protein
Time frame: Change from Baseline and at 8 weeks (end of study)
total cholesterol
Time frame: Change from Baseline and at 8 weeks (end of study)
high-density lipoprotein
Time frame: Change from Baseline and at 8 weeks (end of study)
low-density lipoprotein
Time frame: Change from Baseline and at 8 weeks (end of study)
triglycerides
Time frame: Change from Baseline and at 8 weeks (end of study)
weight
Time frame: Change from Baseline and at 8 weeks (end of study)
height
Time frame: Change from Baseline and at 8 weeks (end of study)
handgrip strength
Time frame: Change from Baseline and at 8 weeks (end of study)
waist circumference
Time frame: Change from Baseline and at 8 weeks (end of study)
calf circumference
Time frame: Change from Baseline and at 8 weeks (end of study)
Ran from May 2021 to primary completion in Jul 2021, 2 months.
Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's 2 months is below that.
Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
Santa Catarina Federal University